Ramipril - Hypertension

Sanofi

Status and phase: Completed; Phase 4

Conditions: Hypertension

Treatments: Drug: Ramipril

Study type: Interventional

Funder types: Industry

Identifiers

NCT00325806

HOE498_3E03

Details and patient eligibility

About

Primary objective:

Mean values of systolic and diastolic office blood pressure

Secondary objectives:

Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

Enrollment: 1,008 patients

Sex: All

Ages: 50 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• no previous antihypertensive therapy
• high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg)

Exclusion criteria

• antihypertensive therapy
• blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)